by Peter Ciszewski | Jul 27, 2021
Thanos Zomas, MD, from Takeda Oncology, discusses follow-up data from the ECHELON-1 study presented at EHA 2021 and ASCO 2021. The ECHELON-1 study was an open-label, randomized, phase 3 study comparing brentuximab vedotin (Adcetris; A) in combination with...
by Peter Ciszewski | Jul 26, 2021
Brenton Mar, MD, PhD, Senior Medical Director at Blueprint Medicines, discusses the recent approval of avapritinib (brand name: Ayvakit) for the treatment of adult patients with advanced systemic mastocytosis. Systemic mastocytosis is a rare, hematologic...
by Peter Ciszewski | Jul 23, 2021
Daniel Auclair, MD, Chief Scientific Officer of the Multiple Myeloma Research Foundation (MMRF), discusses the foundation’s history and what they are currently doing to progress multiple myeloma research. Multiple myeloma is a rare blood cancer associated with...
by Peter Ciszewski | Jul 23, 2021
Sharon Hrynkow, MD, Chief Scientific Officer and Senior VP for Medical Affairs, Cyclo Therapeutics, discusses the phase 3 TransportNPC study evaluating hydroxypropyl betacyclodextrin (Trappsol® Cyclo™) for the treatment of Niemann-Pick disease type C1...
by Peter Ciszewski | Jul 22, 2021
Roman Groisberg, MD, Medical Oncologist and Director of the Sarcoma Program at Rutgers Cancer Institute of New Jersey/RWJBarnabas Health, discusses the difficulties of diagnosing sarcomas. Sarcomas are rare cancers that develop in the bones and soft tissues,...
